Results 211 to 220 of about 44,405 (256)

Brain linear measurement index in the differential diagnosis between idiopathic normal pressure hydrocephalus and progressive supranuclear palsy. [PDF]

Neurol Sci
Luca A, Donzuso G, Contrafatto F, Mostile G, Cicero CE, Nicoletti A, Zappia M.   +6 more
europepmc   +1 more source

Patterns of Longitudinal Regional Brain Atrophy in Patients With Different Progressive Supranuclear Palsy Clinical Variants. [PDF]

Neurology
Kumar M, Tosakulwong N, Weigand SD, Ali F, Stephens YC, Machulda MM, Schwarz CG, Senjem ML, Jack CR, Josephs KA, Whitwell JL.   +10 more
europepmc   +1 more source

′Hummingbird′ sign in progressive supranuclear palsy

Annals of Indian Academy of Neurology, 2009
Shukla Rakesh, Sinha Manish, Kumar Rajesh, Singh Dilip   +3 more
doaj  

Cerebrospinal fluid biomarkers predict frontotemporal dementia trajectory [PDF]

, 2018
et al,, Fagan, Anne M, Jerome, Gina
core   +1 more source

Noradrenaline for progressive supranuclear palsy syndromes (NORAPS): a randomised, double-blind, placebo-controlled, crossover Phase IIb clinical trial evaluating the efficacy and safety of oral atomoxetine for treating cognitive and behavioural changes in people with progressive supranuclear palsy syndromes in the UK. [PDF]

BMJ Open
Durcan R, Paula H, Ghosh BCP, Street D, High J, McAlister C, Shepstone L, Russell C, Grant K, Igosheva N, Rodgers CT, Jones SP, Ye R, Kobylecki C, Church A, Antoniades C, Marshall V, Passamonti L, Rowe JB.   +18 more
europepmc   +1 more source

Inflammation PET and plasma neurofilament light predict survival in people with progressive supranuclear palsy. [PDF]

Brain Commun
Shapiro NL, Jones PS, Mak E, Tsvetanov KA, Goddard J, Vontobel DS, Durcan R, Chouliaras L, Fryer T, Hong YT, Aigbirhio F, Heslegrave A, Franzmeier N, Brendel M, Zetterberg H, O'Brien JT, Rowe JB, Malpetti M.   +17 more
europepmc   +1 more source